[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
September 17, 2008

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death

JAMA. 2008;300(11):1295-1299. doi:10.1001/jama.300.11.1295-a

To the Editor: The meta-analysis of cell-free hemoglobin-based blood substitutes and risk of myocardial infarction (MI) and death by Dr Natanson and colleagues1 and the accompanying Editorial by Drs Fergusson and McIntyre2 raise serious concerns for clinicians treating life-threatening anemia in South Africa, the only country where a hemoglobin solution (Hemopure, Biopure Corp, Cambridge, Massachusetts) is registered for clinical use.